365体育网投 announces partnership with the Center for Contemporary Sciences
365体育网投, a BICO Company, announced today its partnership with the Center for Contemporary Sciences (CCS), an organization founded by scientists to champion and advance more human-relevant testing methods with industry, policy, and regulators. 365体育网投 will take on a scientific advisory role and lend its industry expertise in existing human-relevant testing methods.
The Center for Contemporary Sciences’ goal is to educate, connect, and support the scientific research industry with modern innovations that replace animal testing. With a science-driven mission that recognizes that animal models are not translatable to human biology, CCS places emphasis on human-relevant methods that currently exist or can be developed, to provide a more accurate human response and bring safer, more efficacious products to market for consumers.
CCS’s mission complements 365体育网投’s mission to support human-relevant research by providing synergistic life science products and services. 365体育网投’s suite of lab-grown human tissue models, including skin, eye, respiratory, gut, and vaginal tissue types, are micro-physiological platforms that recapitulate human biology better than those of whole-animal or animal-derived models, providing a more accessible, cost-effective, and biologically comparable approach to preclinical evaluation for the pharmaceutical, cosmetics, and consumer goods industries.
“Currently, nine out of ten drug formulations that pass the animal tests in preclinical screening will fail in human clinical trials, partly because animal models are not translatable to human biology,” said Kevin Causey, Vice President of Business Development for 365体育网投 Life Sciences. “Our mission overlaps with CCS’s mission to bring better scientific tools to the preclinical testing process that can reduce clinical failures and ultimately bring safer, more efficacious products to market.” He added, “Partnering with CCS to provide consultation on feasible and accessible alternatives for their partners seamlessly blends with our mission and initiatives.”
“The science overwhelmingly shows that animal tests are poorly predictive of human outcomes,” says CCS CEO and Co-founder Aysha Akhtar, MD, MPH. “Patients are desperately in need of treatments that work, and lives remain in the balance as long as we continue unreliable animal testing. We need better methods, and we need them now. Replacing animal testing is a win-win for humans and animals and we are incredibly grateful for the immense experience 365体育网投 brings in human-relevant testing methods.”
ABOUT MATTEK Founded in 1985, 365体育网投 Life Sciences began producing three-dimensional human tissue models as reliable replacements for animal testing. 365体育网投’s physiologically advanced tissue models empower companies in the cosmetics, chemical, and pharmaceutical industries to achieve their goals of non-animal testing while lowering preclinical costs and providing human-relevant results. With locations in Ashland, MA, USA, and Bratislava, Slovakia today 365体育网投’s offerings include skin, eye, oral, respiratory, vaginal, and intestinal tissue models including disease modeling, validated, and custom testing services, multiple donor primary cells, culture media, and highly optical cultureware.
ABOUT THE CENTER FOR CONTEMPORARY SCIENCES CCS a nonprofit organization founded in 2020, is pioneering a paradigm shift towards innovative, evidence-based research methods that are based on human biology. 通过合作, we champion technologies that are better for humans and that replace animal testing.
For further information, please contact:
Margaux Babineau, Director of Marketing & Customer Engagement
Phone (US): +1 (508) 881-6771 X 218